Baxter International Inc.

The filings show a company with growing sales but deteriorating earnings and cash flow in 2025. Revenue rose 5.7% to $11.24 billion, yet operating income moved from $14 million in 2024 to a loss of $308 million, and net loss reached $957 million. Operating cash flow of $845 million was lower than the prior year's $1.02 billion. The Beneish M-Score of -2.621 is below the -1.78 threshold and is not in the elevated manipulation-risk zone. That is a screening result only: it means the model did not flag a manipulation pattern, not that the numbers are proven accurate. The Altman Z-Score of 3.86 falls in the safe zone, which describes balance-sheet distress risk under that model, not profitability. The Piotroski F-Score is 5 of 9 computable signals, a middling reading that reflects the mixed profitability and cash flow picture. The Fog Index of 20.82 is above 18, in the very hard to read band, so the MD&A requires careful effort to parse. The 10-Q market-risk section discloses that a 10% weakening of the U.S. dollar would change a $2 million net pre-tax liability on foreign exchange contracts by $7 million, and that the Turkish subsidiary, reporting under highly inflationary accounting, held $33 million of net monetary assets as of June 30, 2026. Management concluded disclosure controls were effective, but the 10-Q was certified by an Interim Chief Financial Officer, which readers may want to look at alongside the company's governance disclosures.

Catalyst.Revenue for 2025 reached $11.24 billion, up 5.7% from $10.64 billion in 2024. The excerpts provided do not include the full results discussion, so the business drivers are visible mainly through strategic references. The 10-K says Baxter is working to create a more resilient supply chain and better align its manufacturing footprint with commercial activities, and that its R&D is focused on select programs, with R&D spending of $518 million in 2025 versus $590 million in 2024. The 10-Q excerpt reports no share repurchases in the second quarter of 2026 and $1.30 billion remaining under the authorization. Sales growth has not yet carried through to profitability.

Hidden risk.The most material tension is between top-line growth and cash generation. Operating cash flow fell to $845 million in 2025 from $1.02 billion in 2024, while the net loss widened to $957 million from $649 million. Operating cash flow divided by net income is -0.88, which is not a meaningful conversion measure when net income is negative; it only shows that cash flow stayed positive while earnings were negative. Total assets fell to $20.05 billion from $25.78 billion, and long-term debt fell to $9.44 billion from $13.18 billion. The 10-Q states there are no material changes to the risk factors in the 2025 Annual Report, so the dependence on major GPOs, IDNs and single-source suppliers still applies. Readers may want to look at how the company is funding its obligations as the balance sheet shrinks.